Assurex Health and Canada’s Centre for Addiction and Mental Health (CAMH) today announced they have received a $6 million grant from Genome Canada, an agency of the Canadian government, to study the benefits of genetic testing to guide medication decisions for patients with depression or schizophrenia. Read more.
Medicare has issued a Local Coverage Determination (LCD) that will provide coverage for GeneSight Psychotropic, the first combinatorial pharmacogenomic test to help guide medication decisions for depression. Prior to GeneSight, no psychiatric pharmacogenomic test has achieved a favorable coverage decision from Medicare. There is no out-of-pocket cost to Medicare Part B patients. Read more.
In November 2013, CAMH and Assurex Health signed a partnership agreement to bring the benefits of a personalized approach to psychiatric treatment to more Canadians. One year later, Canadian patients enrolled in the IMPACT study are being tested using Assurex Health proprietary technology, GeneSight® Psychotropic. Read more.
